Friday, March 27, 2026 For Patients CME Credits Newsletters
Subscribe

Rheumatology

2 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary Outcome
In a Phase 3 trial with 367 SLE patients, subcutaneous anifrolumab was tested against placebo. The primary endpoint is the BICLA response, but specific statistical outcomes are pending.
Researchers tested a new drug called anifrolumab for patients with lupus who were not improving on standard treatments. The study aimed to see if this drug could help more patients feel better and hav…
Phase III CT.gov n=367 6h ago Read →
Phase 3 Trial of Cenerimod for Lupus Nephritis: Efficacy and Safety Evaluation
A Phase 3 trial is assessing cenerimod's efficacy and safety in treating active lupus nephritis. The primary endpoint is complete renal response (CRR) over a 76-week period.
This study is looking at a new drug called cenerimod to see if it helps improve kidney function in people with lupus nephritis. Researchers will also check for any side effects from the drug.…
Phase III CT.gov n=300 6h ago Read →
CT.gov · Phase 3 Trial Evaluates Safety and Immunogenicity of CHIKV VLP Vaccine in Childr… CT.gov · Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients CT.gov · Ivonescimab Phase II Study Targets 55% DCR in Relapsed Pleural Mesothelioma CT.gov · Phase 2 Study Evaluates Frexalimab, Brivekimig, Rilzabrutinib in FSGS and MCD CT.gov · Phase 2 Study: ManNAc for FSGS Shows Promise in Reducing Proteinuria CT.gov · Phase 3 Trial: Anifrolumab Shows Promise in SLE with BICLA Response as Primary O…